In light of the fact that the expression of genes such as FKBP5 and DUSP1 are known to be induced by glucocorticoid treatment, ATMdexa1 (miniATM RNA) may be a potential molecular blood marker to gauge treatment efficacy and predict outcome in AT patients. This evidence concerns the gene FKBP5 and ataxia telangiectasia.